SANTA CLARA, Calif., March 31, 2025 /PRNewswire-PRWeb/ -- With millions of individuals in LMICs lacking access to timely CD4 testing, the VITA™ Point-of-Care CD4 Test addresses a critical gap in global health. CD4 cell count remains a key indicator in determining treatment decisions for AHD patients, particularly in settings where viral load testing is not widely available. The ability to obtain results within minutes at the point of care ensures that healthcare workers can immediately assess disease progression and initiate life-saving treatment without delay.